Skip to main content

Lentigen Licenses Lentiviral IP from Cambridge

NEW YORK (GenomeWeb News) – Lentigen has licensed an HIV-related lentiviral vector technology patent held by the University of Cambridge, the company said today.
 
Baltimore-based Lentigen signed an exclusive agreement with Cambridge Enterprise, the technology licensing arm of the University of Cambridge, for technology that was developed by Andrew Lever.
 
"The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies," said Boro Dropulic, who is Lentigen’s founder, president, and chief scientific officer.
 
The licensing deal follows the acquisition of Cell Genesys’ lentiviral patent portfolio late last year by GBP Capital, who is Lentigen’s majority shareholder.
 
Financial terms of the agreement were not released.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.